Combined entity will have R&D capabilities and manufacturing capacity.
Novasep reports that it is finalizing discussions to buy PharmaChem Technologies. Customers will now benefit from Novasep’s R&D capabilities and technologies along with PharmaChem’s manufacturing capacity to produce APIs and intermediates.
“Groupe Novasep intends to continue developing PharmaChem’s activities and to build synergies with our Synthesis and Process businesses,” remarks Roger-Marc Nicoud, president of Novasep.
PharmaChem’s has a cGMP-compliant plant based in Freeport, Bahamas. Once the transaction is complete both companies will continue to operate under their current names and management structure.
